Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1

Inclusion Criteria: * Age \> 18 years * Informed consent to participate in the study * HIV infection * Stable antiretroviral therapy (ART) in the six months prior to enrollment without virological failure defined by HIV-RNA\>50 copies/mL in at least two consecutive determinations * Positive HBV anti-core antibodies (HBcAb) in the absence of hepatitis B surface antigen (HBsAg) * Absence of mutations associated with resistance to integrase inhibitors (INSTIs) and reverse transcriptase inhibitors (NNRTIs) by HIV genotypic resistance testing * CD4 Nadir \>200 cells/mm3 Exclusion Criteria: * Any contraindications to the use of one or more long-acting drugs * Non-expression or withdrawal of informed consent to participate in the study * Pregnancy * Lack of HIV genotypic resistance testing * Virological failure (HIV-RNA \>50 copies/mL in at least 2 consecutive determinations) in the 6 months prior to enrollment * Therapeutic interruptions in the six months prior to enrollment, excluding interruptions lasting less than a month due to tolerability * CD4 Nadir =\<200 cells/mm3 * Presence of biochemical signs of hepatocellular necrosis (AST, ALT \> normal values as indicated in laboratory tests). * Cirrhosis and/or fibrosis score \>F3 assessed by transient elastography (FibroScan).